Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction
Evaluation of treatment response in refractory alopecia areata, highlighting predictors and relapse after discontinuation.
Key Points
The aim is to evaluate the real-world effectiveness and safety of baricitinib and ritlecitinib in refractory alopecia areata and identify response predictors.
Retrospective review of 65 adults with refractory alopecia areata.
Scalp regrowth assessed using Severity of Alopecia Tool (SALT) up to Week 52.
Predictors of Week 36 response evaluated using multivariable logistic regression.
Adverse events recorded throughout the study.
42% of baricitinib patients achieved SALT ≤ 20 by Week 36, comparable to 41.7% of ritlecitinib patients.
Disease duration < 2 years and baseline eyebrow loss predicted response in baricitinib cohort.
All four responders who discontinued baricitinib experienced relapse, with a mean of 14.7 weeks.
Among those who reduced dosage, relapse occurred in half of the evaluable cases, mean 24.2 weeks.